Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.4%. By the end of trading, Jazz Pharmaceuticals fell $12.92 (-7.4%) to $162.06 on heavy volume. Throughout the day, 3,547,867 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 927,700 shares. The stock ranged in price between $157.57-$169.80 after having opened the day at $166.09 as compared to the previous trading day's close of $174.98. Other companies within the Health Care sector that declined today were:
), down 17.2%,
), down 14.9%,
), down 11.4% and
), down 7.8%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. Jazz Pharmaceuticals has a market cap of $9.9 billion and is part of the drugs industry. Shares are up 38.3% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.
- You can view the full Jazz Pharmaceuticals Ratings Report.
On the positive front,
), up 33.2%,
), up 26.4%,
), up 19.9% and
), up 14.6% , were all gainers within the health care sector with
) being today's featured health care sector leader.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider
) while those bearish on the health care sector could consider
- Find other investment ideas from our top rated ETFs lists.